Finding a Blockbuster Successor to Lipitor

Finding a Blockbuster Successor to Lipitor

Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had thre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Genetic engineering & biotechnology news 2011-02, Vol.31 (3), p.16-17
1. Verfasser: Dimond, P F
Format: Magazinearticle
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had threatened to market its own version of Lipitor, Pfizer hung on to the majority of the cholesterol-lowering market.
ISSN:1935-472X
DOI:10.1089/gen.31.03.05